Nodal peripheral T-cell lymphoma: Chemotherapy-free management, are we there yet?

被引:3
作者
Macapagal, Sharina C. [1 ,4 ]
Bennani, N. Nora [2 ,3 ]
机构
[1] Mayo Clin, Dept Mol Med, Rochester, MN USA
[2] Mayo Clin, Dept Med, Div Hematol, Rochester, MN USA
[3] Mayo Clin, Coll Med, 200 First St SW, Rochester, MN 55905 USA
[4] Mayo Clin, 200 First St SW, Rochester, MN 55905 USA
关键词
Peripheral T-cell lymphoma; Epigenetic modifiers; Antibody-drug conjugates; Small molecule inhibitors; Oncolytic virotherapy; PROGRAMMED DEATH-1 PD-1; PHASE-I; BRENTUXIMAB VEDOTIN; INHIBITOR; MUTATIONS; ROMIDEPSIN; TRIAL; TET2; REARRANGEMENTS; IMMUNOTHERAPY;
D O I
10.1016/j.blre.2023.101071
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Peripheral T-cell lymphomas (PTCLs) are a diverse and uncommon type of lymphoid malignancies with a dismal prognosis. Recent advances in genomic studies have shown recurring mutations that are changing our knowledge of the disease's molecular genetics and pathogenesis. As such, new targeted therapies and treatments to improve disease outcomes are currently being explored. In this review, we discussed the current understanding of the nodal PTCL biology with potential therapeutic implications and gave our insights on the promising novel therapies that are currently under study such as immunotherapy, chimeric antigen receptor T-cell therapy, and oncolytic virotherapy.
引用
收藏
页数:10
相关论文
共 126 条
  • [1] Peripheral T-cell lymphomas in a large US multicenter cohort: prognostication in the modern era including impact of frontline therapy
    Abramson, J. S.
    Feldman, T.
    Kroll-Desrosiers, A. R.
    Muffly, L. S.
    Winer, E.
    Flowers, C. R.
    Lansigan, F.
    Nabhan, C.
    Nastoupil, L. J.
    Nath, R.
    Goy, A.
    Castillo, J. J.
    Jagadeesh, D.
    Woda, B.
    Rosen, S. T.
    Smith, S. M.
    Evens, A. M.
    [J]. ANNALS OF ONCOLOGY, 2014, 25 (11) : 2211 - 2217
  • [2] The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms
    Alaggio, Rita
    Amador, Catalina
    Anagnostopoulos, Ioannis
    Attygalle, Ayoma D.
    Araujo, Iguaracyra Barreto de Oliveira
    Berti, Emilio
    Bhagat, Govind
    Borges, Anita Maria
    Boyer, Daniel
    Calaminici, Mariarita
    Chadburn, Amy
    Chan, John K. C.
    Cheuk, Wah
    Chng, Wee-Joo
    Choi, John K.
    Chuang, Shih-Sung
    Coupland, Sarah E.
    Czader, Magdalena
    Dave, Sandeep S.
    de Jong, Daphne
    Du, Ming-Qing
    Elenitoba-Johnson, Kojo S.
    Ferry, Judith
    Geyer, Julia
    Gratzinger, Dita
    Guitart, Joan
    Gujral, Sumeet
    Harris, Marian
    Harrison, Christine J.
    Hartmann, Sylvia
    Hochhaus, Andreas
    Jansen, Patty M.
    Karube, Kennosuke
    Kempf, Werner
    Khoury, Joseph
    Kimura, Hiroshi
    Klapper, Wolfram
    Kovach, Alexandra E.
    Kumar, Shaji
    Lazar, Alexander J.
    Lazzi, Stefano
    Leoncini, Lorenzo
    Leung, Nelson
    Leventaki, Vasiliki
    Li, Xiao-Qiu
    Lim, Megan S.
    Liu, Wei-Ping
    Louissaint, Abner, Jr.
    Marcogliese, Andrea
    Medeiros, L. Jeffrey
    [J]. LEUKEMIA, 2022, 36 (07) : 1720 - 1748
  • [3] Therapy-related myeloid neoplasms following chimeric antigen receptor T-cell therapy for Non-Hodgkin Lymphoma
    Alkhateeb, Hassan B.
    Mohty, Razan
    Greipp, Patricia
    Bansal, Radhika
    Hathcock, Matthew
    Rosenthal, Allison
    Murthy, Hemant
    Kharfan-Dabaja, Mohamed
    Bisneto Villasboas, Jose C.
    Bennani, Nora
    Ansell, Stephen M.
    Patnaik, Mrinal M.
    Litzow, Mark R.
    He, Rong
    Chen, Dong
    Al-Kali, Aref
    Kenderian, Saad S.
    Lin, Yi
    Shah, Mithun Vinod
    [J]. BLOOD CANCER JOURNAL, 2022, 12 (07)
  • [4] Therapy of Peripheral T Cell Lymphoma: Focus on Nodal Subtypes
    Allen, Pamela B.
    Pro, Barbara
    [J]. CURRENT ONCOLOGY REPORTS, 2020, 22 (05)
  • [5] Altinay S, 2022, ANTI-CANCER AGENT ME, V23, P298
  • [6] A phase 1 study of romidepsin and pralatrexate reveals marked activity in relapsed and refractory T-cell lymphoma
    Amengual, Jennifer E.
    Lichtenstein, Renee
    Lue, Jennifer
    Sawas, Ahmed
    Deng, Changchun
    Lichtenstein, Emily
    Khan, Karen
    Atkins, Laine
    Rada, Aishling
    Kim, Hye A.
    Chiuzan, Codruta
    Kalac, Matko
    Marchi, Enrica
    Falchi, Lorenzo
    Francescone, Mark A.
    Schwartz, Lawrence
    Cremers, Serge
    O'Connor, Owen A.
    [J]. BLOOD, 2018, 131 (04) : 397 - 407
  • [7] Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma
    Andtbacka, Robert H. I.
    Kaufman, Howard L.
    Collichio, Frances
    Amatruda, Thomas
    Senzer, Neil
    Chesney, Jason
    Delman, Keith A.
    Spitler, Lynn E.
    Puzanov, Igor
    Agarwala, Sanjiv S.
    Milhem, Mohammed
    Cranmer, Lee
    Curti, Brendan
    Lewis, Karl
    Ross, Merrick
    Guthrie, Troy
    Linette, Gerald P.
    Daniels, Gregory A.
    Harrington, Kevin
    Middleton, Mark R.
    Miller, Wilson H., Jr.
    Zager, Jonathan S.
    Ye, Yining
    Yao, Bin
    Li, Ai
    Doleman, Susan
    VanderWalde, Ari
    Gansert, Jennifer
    Coffin, Robert S.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (25) : 2780 - U98
  • [8] Phase I Study of the CD47 Blocker TTI-621 in Patients with Relapsed or Refractory Hematologic Malignancies
    Ansell, Stephen M.
    Maris, Michael B.
    Lesokhin, Alexander M.
    Chen, Robert W.
    Flinn, Ian W.
    Sawas, Ahmed
    Minden, Mark D.
    Villa, Diego
    Percival, Mary-Elizabeth M.
    Advani, Anjali S.
    Foran, James M.
    Horwitz, Steven M.
    Mei, Matthew G.
    Zain, Jasmine
    Savage, Kerry J.
    Querfeld, Christiane
    Akilov, Oleg E.
    Johnson, Lisa D. S.
    Catalano, Tina
    Petrova, Penka S.
    Uger, Robert A.
    Sievers, Eric L.
    Milea, Anca
    Roberge, Kathleen
    Shou, Yaping
    O'Connor, Owen A.
    [J]. CLINICAL CANCER RESEARCH, 2021, 27 (08) : 2190 - 2199
  • [9] Romidepsin Plus CHOP Versus CHOP in Patients With Previously Untreated Peripheral T-Cell Lymphoma: Results of the Ro-CHOP Phase III Study (Conducted by LYSA)
    Bachy, Emmanuel
    Camus, Vincent
    Thieblemont, Catherine
    Sibon, David
    Casasnovas, Rene-Olivier
    Ysebaert, Loic
    Damaj, Gandhi
    Guidez, Stephanie
    Pica, Gian Matteo
    Kim, Won Seog
    Lim, Soon Thye
    Andre, Marc
    Garcia-Sancho, Alejandro Martin
    Penarrubia, Maria Jesus
    Staber, Philipp B.
    Trotman, Judith
    Huettmann, Andreas
    Stefoni, Vittorio
    Re, Alessandro
    Gaulard, Philippe
    Delfau-Larue, Marie-Helene
    de Leval, Laurence
    Meignan, Michel
    Li, Ju
    Morschhauser, Franck
    Delarue, Richard
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (03) : 242 - +
  • [10] Phase II Study of the PD-1 Inhibitor Pembrolizumab for the Treatment of Relapsed or Refractory Mature T-cell Lymphoma
    Barta, Stefan K.
    Zain, Jasmine
    MacFarlane, Alexander W.
    Smith, Sonali M.
    Ruan, Jia
    Fung, Henry C.
    Tan, Carlyn R.
    Yang, Yibin
    Alpaugh, R. Katherine
    Dulaimi, Essel
    Ross, Eric A.
    Campbell, Kerry S.
    Khan, Nadia
    Siddharta, Rawat
    Fowler, Nathan H.
    Fisher, Richard, I
    Oki, Yasuhiro
    [J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (06) : 356 - +